<p>In this discussion, Dr Tanenbaum and Suzie Bash, MD, a Medical Director at RadNet in Los Angeles, cover the intersection of disease-modifying therapies (DMTs), quantitative imaging, and artificial intelligence (AI) in managing Alzheimer disease.</p>

In this discussion, Dr Tanenbaum and Suzie Bash, MD, a Medical Director at RadNet in Los Angeles, cover the intersection of disease-modifying therapies (DMTs), quantitative imaging, and artificial intelligence (AI) in managing Alzheimer disease.

Disease-Modifying Therapy, Quantitative Imaging, and AI for Managing Patients with Alzheimer Disease

Moderated by Lawrence Tanenbaum, MD, FACR, Applied Radiology hosted a series of conversations with experts in Alzheimer disease imaging and management at the 2024 Radiological Society of North America Annual Meeting and Scientific Exhibition.

Share Disease-Modifying Therapy, Quantitative Imaging, and AI for Managing Patients with Alzheimer Disease

Sign up to save your podcasts

Disease-Modifying Therapy, Quantitative Imaging, and AI for Managing Patients with Alzheimer Disease

Disease-Modifying Therapy, Quantitative Imaging, and AI for Managing Patients with Alzheimer Disease